The Menopausal Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Menopausal Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Menopausal Disorders. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Menopausal Disorders - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Menopausal Disorders and features dormant and discontinued products.

GlobalData tracks 26 drugs in development for Menopausal Disorders by 25 companies/universities/institutes. The top development phase for Menopausal Disorders is phase ii with nine drugs in that stage. The Menopausal Disorders pipeline has 25 drugs in development by companies and one by universities/ institutes. Some of the companies in the Menopausal Disorders pipeline products market are: Viramal, Iaterion and Cosette Pharmaceuticals.

The key targets in the Menopausal Disorders pipeline products market include Estrogen Receptor (ESR), Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2), and Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR).

The key mechanisms of action in the Menopausal Disorders pipeline product include Estrogen Receptor (ESR) Agonist with seven drugs in Phase III. The Menopausal Disorders pipeline products include seven routes of administration with the top ROA being Oral and three key molecule types in the Menopausal Disorders pipeline products market including Small Molecule, and Cell Therapy.

Menopausal Disorders overview

Menopausal disorders encompass a range of symptoms and health issues that arise during and after menopause, a natural biological process marking the end of a woman’s reproductive years. Common menopausal symptoms include hot flashes, night sweats, mood swings, and changes in sleep patterns. Hormonal fluctuations during this transition can also lead to conditions such as vaginal atrophy, affecting the genital tissues, and osteoporosis, a loss of bone density. Additionally, menopausal women may experience challenges related to sexual health and emotional well-being. Management often involves hormone replacement therapy, lifestyle modifications, and medications to address specific symptoms and reduce long-term health risks associated with hormonal changes. Regular medical check-ups and open communication with healthcare providers play a crucial role in navigating menopausal disorders effectively.

For a complete picture of Menopausal Disorders’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.